Market Overview

UPDATE: Aegis Capital Corp. Initiates Coverage on Galena Biopharma with Buy Rating, $6 PT

Related GALE
Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Clinical Trial Data At The 56th American Society of
UPDATE: MLV & Co Reiterates On Galena Biopharma As External Risks Have Subsided

In a report published Wednesday, Aegis Capital Corp. initiated coverage on Galena Biopharma (NASDAQ: GALE) with a Buy rating and $6.00 price target.

Aegis Capital noted, “Galena is an emerging biotechnology firm developing a novel immunotherapeutic approach to combating the recurrence of breast cancer in patients with minimal residual disease. The firm's lead candidate, NeuVax (E75 / nelipepimut), is a peptide vaccine that is derived from the extracellular domain of the HER2/neu cell surface receptor protein. The HER2/neu protein is one of the world's most recognizable oncogene products, and is the target of several widelyused breast cancer therapeutic agents, including the blockbuster monoclonal antibody product Herceptin (trastuzumab), marketed by Roche / Genentech (RHHBY.PK, Not Rated). In our view, Galena represents an attractive investment opportunity because it is focusing on a validated target, possesses a solid data foundation showing that its vaccine is active in human subjects, and is conducting a Phase 3 trial of the vaccine that is slated to report interim data in late 2013/early 2014.”

Galena Biopharma closed on Tuesday at $1.69.

Latest Ratings for GALE

DateFirmActionFromTo
Nov 2014MLV & Co.ReiteratesBuy
Nov 2014Cantor FitzgeraldMaintainsSell
Mar 2014McNicoll Lewis VlakMaintainsBuy

View More Analyst Ratings for GALE
View the Latest Analyst Ratings

Posted-In: Aegis Capital Corp.Analyst Color Initiation Analyst Ratings

 

Related Articles (GALE)

Around the Web, We're Loving...

Get Benzinga's Newsletters